Incannex (ASX:IHL) share price flat after earnings report

Shares in the medicinal cannabis company remain in the starter block today despite progress detailed in its quarterly results.

| More on:
range of hemp oil and skin products representing elixinol share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price has remained flat in this morning's trade, without any excitement either way.

Incannex shares haven't budged despite the healthcare company providing an update on its progress for the quarter ending 30 June 2021.

At the time of writing, the Incannex share price is 25 cents, in line with the market open.

Let's take a closer look at what the company released.

Quick refresher on Incannex Healthcare

Incannex is a clinical-stage medicinal cannabis company. It has four significant clinical programs for its products underway in pursuit of regulatory approval in the US.

These programs cover conditions such as sleep apnoea (OSA), traumatic brain injury (TBI) and temporomandibular joint disorder (TMJD).

At the time of writing, Incannex has a market capitalisation of $267 million.

Quarterly results

Incannex achieved several progress points across the most recent quarter, as detailed in the report.

Firstly, it realised a total of $133k in cash inflow "associated with the sale of unregistered cannabinoid oils".

This was offset by a net cash outflow of $2.175 million that was designated for research and development (R&D) expenditures.

Additionally, the company completed its clinical trial protocol for "psilocybin-assisted psychotherapy" in the treatment of generalised anxiety disorder.

Incannex advised that recruitment of therapists for this program would be finalised and their training commence in the upcoming quarters.

Moreover, the company engaged with the University of Western Australia "as an additional site" to its phase 2b clinical trial investigating its products in OSA.

Earlier in July, the company had filed an international patent application for these formulations in the United States, European Union, Japan and Australia.

In addition, Incannex also expanded its clinical program to examine the effects of its products in inflammatory conditions such as bronchitis, rheumatoid arthritis and inflammatory bowel disease.

Furthermore, the company is investigating the delivery of its oils via gel capsules in a clinical trial, engaging Procaps S.A, a "GMP compliant manufacturer", to produce its capsules.

Incannex said Procaps had the capacity to "quickly ramp up production to commercial quantities" should the clinical trial be successful.

Finally, Incannex has also entered into a collaboration with Vectura Ltd to develop the "formulation" of one of its compounds, to be "used in clinical trials" against TBI.

Incannex share price snapshot

The Incannex share price has posted a year to date return of 61%, extending the previous 12 month's return of 267%.

These returns have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of ~23% over the past year.

Additionally, the Incannex share price has climbed ~6 over the past 1 month.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

A man in a horse head mask and suit jumps for joy on a beach.
Cannabis Shares

Could ASX cannabis shares be set for a smoking hot rebound?

ASX cannabis stocks could be set for a strong finish to 2024.

Read more »

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »